Open Access

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

  • John Bridgewater1Email author,
  • Andre Lopes2,
  • Sandra Beare2,
  • Marian Duggan2,
  • Dymphna Lee2,
  • Maravic Ricamara1,
  • Delyth McEntee3,
  • Ajithkumar Sukumaran4,
  • Harpreet Wasan4 and
  • Juan W. Valle3
BMC Cancer201616:369

https://doi.org/10.1186/s12885-016-2403-1

Received: 15 June 2016

Accepted: 15 June 2016

Published: 21 June 2016

The original article was published in BMC Cancer 2016 16:153

Erratum

After publication of the original article [1], the authors noticed an error in the Acknowledgements section. The Acknowledgement contains missing information. The correct version of the Acknowledgements section is included below:

Notes

Declarations

Acknowledgements

The research was funded in part by AstraZeneca and carried out at, and supported by, the National Institute for Health Research (NIHR UCLH Clinical Research Facility and the Cancer Research UK Experimental Cancer Medicine Centre (ECMC). Central coordination of the study was supported by Cancer Research UK (Grant reference C1813/A12155) and AstraZeneca. Conduct of the trial at hospital sites was supported through the National Institute of Health Research Clinical Research Network and AstraZeneca. We also acknowledge the support of the AMMF (www.ammf.org.uk/) and the IBTCC (International Biliary Tract Cancer Collaboration). JB is partly funded by the UCLH/UCL NIHR Biomedical Research Centre.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
UCL Cancer Institute
(2)
Cancer Research UK and UCL Clinical Trials Centre
(3)
The Christie NHS Foundation Trust
(4)
Imperial College Healthcare

References

  1. Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16:153. doi:https://doi.org/10.1186/s12885-016-2174-8.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement